4//SEC Filing
OXFORD BIOSCIENCE PARTNERS IV LP 4
Accession 0001270102-05-000004
CIK 0000892112other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 7:04 PM ET
Size
25.6 KB
Accession
0001270102-05-000004
Insider Transaction Report
Form 4
OXFORD BIOSCIENCE PARTNERS IV LP
10% Owner
Transactions
- Purchase
Warrant (right to buy)
2004-12-30+8,130→ 8,130 total(indirect: By mRNA Fund II L.P.)Exercise: $2.52From: 2004-12-30Exp: 2005-02-07→ Common Stock (8,130 underlying) - Exercise of In-Money
Common Stock
2004-12-30$2.52/sh+810,315$2,041,994→ 4,569,545 total - Exercise of In-Money
Common Stock
2004-12-30$2.52/sh+8,130$20,488→ 45,849 total(indirect: By mRNA Fund II L.P.) - Expiration (Short)
Warrant (right to buy)
2004-12-30−810,315→ 0 totalExercise: $2.52From: 2003-02-11Exp: 2008-02-11→ Common Stock (810,315 underlying) - Expiration (Short)
Warrant (right to buy)
2004-12-30−8,130→ 0 total(indirect: By mRNA Fund II L.P.)Exercise: $2.52From: 2003-02-11Exp: 2008-02-11→ Common Stock (8,130 underlying) - Purchase
Warrant (right to buy)
2004-12-30+810,315→ 810,315 totalExercise: $2.52From: 2004-12-30Exp: 2005-02-07→ Common Stock (810,315 underlying) - Exercise of In-Money
Warrant (right to buy)
2004-12-30−810,315→ 891,346 totalExercise: $2.52From: 2004-12-30Exp: 2005-02-07→ Common Stock (810,315 underlying) - Purchase
Warrant (right to buy)
2004-12-30+891,346→ 1,701,661 totalExercise: $3.85From: 2004-12-30Exp: 2009-12-30→ Common Stock (891,346 underlying) - Purchase
Warrant (right to buy)
2004-12-30+8,943→ 17,073 total(indirect: By mRNA Fund II L.P.)Exercise: $3.85From: 2004-12-30Exp: 2009-12-30→ Common Stock (8,943 underlying) - Exercise of In-Money
Warrant (right to buy)
2004-12-30−8,130→ 8,943 total(indirect: By mRNA Fund II L.P.)Exercise: $2.52From: 2004-12-30Exp: 2005-02-07→ Common Stock (8,130 underlying)
Footnotes (4)
- [F1]The reporting person shares a common general partner with the partnership that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities.
- [F2]The reporting person exchanged, in an issuer exchange, a warrant to purchase 810,315 shares of Common Stock for (i) a warrant to purchase 810,315 shares of Common Stock exercisable by payment with cash only and (ii) a warrant to purchase 891,346 shares of Common Stock exercisable by net issuance or by payment with cash.
- [F3]The exercise price (subject to adjustment in the event of stock splits, reverse stock splits, stock dividends, recapitalizations, or similar events) is equal to (i) in the event of a private placement for the primary purpose of raising capital for the Company on or before June 30, 2005, the lower of $3.85 per share and the lowest price per share of Common Stock sold in any such private placement that closes after December 30, 200 and on or before June 30, 2005 or (ii) if no such private placement occurs by June 30, 2005, the lower of $3.85 per share and the average closing selling price of a share of Common Stock traded on the Nasdaq National Market, as quoted in The Wall Street Journal, over the 15-day period ending on June 30, 2005.
- [F4]mRNA Fund II L.P. exchanged, in an issuer exchange, a warrant to purchase 8,130 shares of Common Stock for (i) a warrant to purchase 8,130 shares of Common Stock exercisable by payment with cash only and (ii) a warrant to purchase 8,943 shares of Common Stock exercisable by net issuance or by payment with cash.
Documents
Issuer
SIRNA THERAPEUTICS INC
CIK 0000892112
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001140484
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 7:04 PM ET
- Size
- 25.6 KB